Literature DB >> 20205479

Radiosynthesis and bioimaging of the tuberculosis chemotherapeutics isoniazid, rifampicin and pyrazinamide in baboons.

Li Liu1, Youwen Xu, Colleen Shea, Joanna S Fowler, Jacob M Hooker, Peter J Tonge.   

Abstract

The front-line tuberculosis (TB) chemotherapeutics isoniazid (INH), rifampicin (RIF), and pyrazinamide (PZA) have been labeled with carbon-11 and the biodistribution of each labeled drug has been determined in baboons using positron emission tomography (PET). Each radiosynthesis and formulation has been accomplished in 1 h, using [(11)C]CH(3)I to label RIF and [(11)C]HCN to label INH and PZA. Following iv administration, INH, PZA, RIF, and/or their radiolabeled metabolites clear rapidly from many tissues; however, INH, PZA, and/or their radiolabeled metabolites accumulate in the bladder while RIF and/or its radiolabeled metabolites accumulates in the liver and gall bladder, consistent with the known routes of excretion of the drugs. In addition, the biodistribution data demonstrate that the ability of the three drugs and their radiolabeled metabolites to cross the blood-brain barrier decreases in the order PZA > INH > RIF, although in all cases the estimated drug concentrations are greater than the minimum inhibitory concentration (MIC) values for inhibiting bacterial growth of Mycobacterium tuberculosis (MTB). The pharmacokinetic (PK) and drug distribution data have important implications for treatment of disseminated TB in the brain and pave the way for imaging the distribution of the pathogen in vivo.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20205479      PMCID: PMC2866172          DOI: 10.1021/jm901858n

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  42 in total

1.  Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges.

Authors:  R Nau; H W Prange; S Menck; H Kolenda; K Visser; J K Seydel
Journal:  J Antimicrob Chemother       Date:  1992-06       Impact factor: 5.790

2.  The global tuberculosis situation and the new control strategy of the World Health Organization.

Authors:  A Kochi
Journal:  Tubercle       Date:  1991-03

Review 3.  The penetration of antibiotics into cerebrospinal fluid and brain tissue.

Authors:  R W Barling; J B Selkon
Journal:  J Antimicrob Chemother       Date:  1978-05       Impact factor: 5.790

4.  Pharmacokinetics of pyrazinamide and its metabolites in healthy subjects.

Authors:  C Lacroix; T P Hoang; J Nouveau; C Guyonnaud; G Laine; H Duwoos; O Lafont
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

5.  Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention.

Authors:  J B Bass; L S Farer; P C Hopewell; R O'Brien; R F Jacobs; F Ruben; D E Snider; G Thornton
Journal:  Am J Respir Crit Care Med       Date:  1994-05       Impact factor: 21.405

6.  Cerebrospinal fluid drug concentrations and the treatment of tuberculous meningitis.

Authors:  G A Ellard; M J Humphries; B W Allen
Journal:  Am Rev Respir Dis       Date:  1993-09

7.  Penetration of rifampicin into the brain tissue and cerebral extracellular space of rats.

Authors:  T Mindermann; H Landolt; W Zimmerli; Z Rajacic; O Gratzl
Journal:  J Antimicrob Chemother       Date:  1993-05       Impact factor: 5.790

8.  British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children.

Authors:  Guy Thwaites; Martin Fisher; Cheryl Hemingway; Geoff Scott; Tom Solomon; John Innes
Journal:  J Infect       Date:  2009-07-04       Impact factor: 6.072

9.  The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis.

Authors:  Y Zhang; B Heym; B Allen; D Young; S Cole
Journal:  Nature       Date:  1992-08-13       Impact factor: 49.962

Review 10.  Tuberculosis: commentary on a reemergent killer.

Authors:  B R Bloom; C J Murray
Journal:  Science       Date:  1992-08-21       Impact factor: 47.728

View more
  25 in total

1.  Noninvasive 11C-rifampin positron emission tomography reveals drug biodistribution in tuberculous meningitis.

Authors:  Elizabeth W Tucker; Beatriz Guglieri-Lopez; Alvaro A Ordonez; Brittaney Ritchie; Mariah H Klunk; Richa Sharma; Yong S Chang; Julian Sanchez-Bautista; Sarah Frey; Martin A Lodge; Steven P Rowe; Daniel P Holt; Jogarao V S Gobburu; Charles A Peloquin; William B Mathews; Robert F Dannals; Carlos A Pardo; Sujatha Kannan; Vijay D Ivaturi; Sanjay K Jain
Journal:  Sci Transl Med       Date:  2018-12-05       Impact factor: 17.956

Review 2.  Pharmacologic considerations in use and development of antituberculosis drugs.

Authors:  Geraint Davies
Journal:  Cold Spring Harb Perspect Med       Date:  2014-09-18       Impact factor: 6.915

Review 3.  (11)C[double bond, length as m-dash]O bonds made easily for positron emission tomography radiopharmaceuticals.

Authors:  Benjamin H Rotstein; Steven H Liang; Michael S Placzek; Jacob M Hooker; Antony D Gee; Frédéric Dollé; Alan A Wilson; Neil Vasdev
Journal:  Chem Soc Rev       Date:  2016-08-22       Impact factor: 54.564

Review 4.  The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells.

Authors:  Véronique Dartois
Journal:  Nat Rev Microbiol       Date:  2014-02-03       Impact factor: 60.633

Review 5.  Quantitative PET of liver functions.

Authors:  Susanne Keiding; Michael Sørensen; Kim Frisch; Lars C Gormsen; Ole Lajord Munk
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-04-25

6.  Isolated Splenic Tuberculosis Masquerading as Disease Progression of Hodgkin's Lymphoma on Interim18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Scan.

Authors:  Sudip Dey; Nitin Gupta; Ritu Verma; Nikhil Seniaray; Ethel Shangne Belho; Shashi Dhawan
Journal:  Indian J Nucl Med       Date:  2021-03-04

7.  Dynamic imaging in patients with tuberculosis reveals heterogeneous drug exposures in pulmonary lesions.

Authors:  Alvaro A Ordonez; Hechuan Wang; Gesham Magombedze; Camilo A Ruiz-Bedoya; Shashikant Srivastava; Allen Chen; Elizabeth W Tucker; Michael E Urbanowski; Lisa Pieterse; E Fabian Cardozo; Martin A Lodge; Maunank R Shah; Daniel P Holt; William B Mathews; Robert F Dannals; Jogarao V S Gobburu; Charles A Peloquin; Steven P Rowe; Tawanda Gumbo; Vijay D Ivaturi; Sanjay K Jain
Journal:  Nat Med       Date:  2020-02-17       Impact factor: 53.440

8.  Deoxyfluoro-d-trehalose (FDTre) analogues as potential PET probes for imaging mycobacterial infection.

Authors:  Sarah R Rundell; Zachary L Wagar; Lisa M Meints; Claire D Olson; Mara K O'Neill; Brent F Piligian; Anne W Poston; Robin J Hood; Peter J Woodruff; Benjamin M Swarts
Journal:  Org Biomol Chem       Date:  2016-08-25       Impact factor: 3.876

9.  Radiolabelling and positron emission tomography of PT70, a time-dependent inhibitor of InhA, the Mycobacterium tuberculosis enoyl-ACP reductase.

Authors:  Hui Wang; Li Liu; Yang Lu; Pan Pan; Jacob M Hooker; Joanna S Fowler; Peter J Tonge
Journal:  Bioorg Med Chem Lett       Date:  2015-07-14       Impact factor: 2.823

10.  Noninvasive determination of 2-[18F]-fluoroisonicotinic acid hydrazide pharmacokinetics by positron emission tomography in Mycobacterium tuberculosis-infected mice.

Authors:  E A Weinstein; L Liu; A A Ordonez; H Wang; J M Hooker; P J Tonge; S K Jain
Journal:  Antimicrob Agents Chemother       Date:  2012-09-24       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.